Posted by Michael Wonder on 01 Feb 2024
Adaptimmune announces US FDA acceptance of biologics license application for afami-cel for the treatment of advanced synovial sarcoma with priority review
31 January 2024 - Adaptimmune Therapeutics today announced that the US FDA has accepted for priority review its biologics license application for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma.
The application has a Prescription Drug User Fee Act target action date of 4 August 2024.
